The prevention of cardiovascular disease in cancer survivors

Texas Heart Institute Journal

Volumn 39, Issue 2, 2012, Pages 190-198

  Daher, Iyad N ^a   Daigle, Tina R ^b   Bhatia, Nirmanmoh ^b   Durand, Jean Bernard ^b  

^a Cardiovascular Medicine Associates   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracyclines adverse effects; Antineoplastic agents adverse effects; Atherosclerosis; Calcinosis etiology; Cancer; Cardiomyopathies etiology prevention Control; Cardiotoxins; Cardiovascular diseases chemically induced prevention Control; Carotid artery diseases; Disease progression; Heart failure etiology; Heart drug effects; Heart radiation effects; Monitoring; Physiologic; Radiation injuries; Risk factors; Survivorship

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN; HYDRALAZINE; LOW DENSITY LIPOPROTEIN; SORAFENIB; SUNITINIB; TRASTUZUMAB; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DEVICE THERAPY; DIABETES MELLITUS; DIET THERAPY; DYSLIPIDEMIA; ECG ABNORMALITY; FEMALE; HEART LEFT VENTRICLE FAILURE; HODGKIN DISEASE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERICARDIAL DISEASE; PREVALENCE; RADIATION INJURY; RISK REDUCTION; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CHILD; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; PREVENTIVE HEALTH SERVICES; RADIATION INJURIES; RADIOTHERAPY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TEXAS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863915229     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010 [published erratum appears in CA Cancer J Clin 2011;61(2):133- 4]. CA Cancer J Clin 2010;60(5):277-300.
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER cancer statistics review, 1975-2007. Bethesda (MD): National Cancer Institute; 2010. Available from: http://seer.cancer.gov/csr/1975_2007/ [cited 2011 Jan 23].
3. Ganz PA. Survivorship: adult cancer survivors. Prim Care 2009;36(4):721-41.
4. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al., editors. SEER cancer statistics review, 1975-2006. Bethesda (MD): National Cancer Institute; 2009. Available from: http://seer.cancer.gov/csr/1975_2006/ [cited 2011 Jan 23].
5. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 2003;58(1):82-91.
6. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100(19):1368-1379.
7. Adams MJ, Lipshultz SE. Pathophysiology of anthracyclineand radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005;44(7): 600-606.
8. Hampton T. Cancer therapy can be hard on the heart: researchers aim to explain--and avoid--cardiotoxicity. JAMA 2010;303(11):1019-1020.
9. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25(25): 3991-4008.
10. Enright KA, Krzyzanowska MK. Control of cardiovascular risk factors among adult cancer survivors: a population-based survey. Cancer Causes Control 2010;21(11):1867-1874.
11. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117(6):743-753.
12. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.
13. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31(6):459-467.
14. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6(8): 465-77.
15. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure) [published erratum appears in J Am Coll Cardiol 2006;47(7)1503-5]. J Am Coll Cardiol 2005;46(6):e1-e82.
16. Jarfelt M, Kujacic V, Holmgren D, Bjarnason R, Lannering B. Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007;49(6): 835-840.
17. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42(4):743-749.
18. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22(15):3139-3148.
19. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270(16):1949-1955.
20. Glanzmann C, Huguenin P, Lutolf UM, Maire R, Jenni R, Gumppenberg V. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1994;30(1):43-54.
21. Rutqvist LE, Johansson H. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866-868.
22. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99(5):365-3675.
23. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy- induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114(23):2474-2481.
24. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31(6 Suppl 13):161-181.
25. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 2004;100(10):2052-2063.
26. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001;48(4):297-304.
27. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303(20):2043-2050.
28. Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer 2009;124(5):1213-1219.
29. Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 2007;7(2):122-128.
30. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol 2010;28 (8):1276-81.
31. Agabiti-Rosei E, Muiesan ML. Carotid atherosclerosis, arterial stiffness and stroke events. Adv Cardiol 2007;44:173-186.
32. Carmody BJ, Arora S, Avena R, Curry KM, Simpkins J, Cosby K, Sidawy AN. Accelerated carotid artery disease after highdose head and neck radiotherapy: is there a role for routine carotid duplex surveillance? J Vasc Surg 1999;30(6):1045-1051.
33. Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 2002;13(4):503-512.
34. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002;13(6):819-829.
35. van der Pal HJ, van Dalen EC, Kremer LC, Bakker PJ, van Leeuwen FE. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat Rev 2005;31(3):173-185.
36. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-952.
37. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782-788.
38. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-869.
39. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138(7):542-549.
40. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43(6):1019-1026.
41. McMinn TR Jr, Ross J Jr. Hereditary dilated cardiomyopathy. Clin Cardiol 1995;18(1):7-15.
42. Sung RY, Huang GY, Shing MK, Oppenheimer SJ, Li CK, Li CK, et al. Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol 1997;60(3):239-248.
43. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril- Digoxin Multicenter Research Group. JAMA 1988;259(4): 539-544.
44. Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(6 Suppl):VI78-VI87.
45. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83(5):1774-1777.
46. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101(4):812-818.
47. Jugdutt BI, Khan MI. Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction. Circulation 1994;89(5):2297-2307.
48. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31(6):1352-1356.
49. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84(1):35-39.
50. Chaudhry PA, Mishima T, Sharov VG, Hawkins J, Alferness C, Paone G, Sabbah HN. Passive epicardial containment prevents ventricular remodeling in heart failure. Ann Thorac Surg 2000;70(4):1275-1280.
51. Di Donato M, Toso A, Maioli M, Sabatier M, Stanley AW Jr, Dor V; RESTORE Group. Intermediate survival and predictors of death after surgical ventricular restoration. Semin Thorac Cardiovasc Surg 2001;13(4):468-475.
52. Menicanti L, Di Donato M. The Dor procedure: what has changed after fifteen years of clinical practice? J Thorac Cardiovasc Surg 2002;124(5):886-890.
53. Athanasuleas CL, Stanley AW Jr, Buckberg GD, Dor V, Di Donato M, Blackstone EH. Surgical anterior ventricular en docardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol 2001;37(5):1199-1209.
54. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group [published errata appear in N Engl J Med 2000;343(12):896 and N Engl J Med 2000;343(20):1504]. N Engl J Med 2000;343(4):246-253.
55. Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 1997;12(9):523-5230.
56. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30(2):518-526.
57. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003;290(21):2831-2837.
58. Ruckdeschel JC, Chang P, Martin RG, Byhardt RW, O'Connell MJ, Sutherland JC, Wiernik PH. Radiation-related pericardial effusions in patients with Hodgkin's disease. Medicine (Baltimore) 1975;54(3):245-259.
59. Rosvall M, Janzon L, Berglund G, Engstrom G, Hedblad B. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med 2005;257 (5):430-437.
60. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010;303(16):1610-1616.
61. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals [published erratum appears in JAMA 2004;291(5):563]. JAMA 2004;291(2):210-215.
62. Rademaker J, Schoder H, Ariaratnam NS, Strauss HW, Yahalom J, Steingart R, Oeffinger KC. Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR Am J Roentgenol 2008;191(1):32-37.
63. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute [published erratum appears in Circulation 2006;113(22):e847]. Circulation 2006;113(19):2363-2372.
64. Kent SM, Taylor AJ. Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection. Am J Cardiol 2003;92(10):1224-1227.
65. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252.
66. Ferrari R, Guardigli G, Ceconi C. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drugs Ther 2010;24(4):331-339.
67. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343(1):16-22.